HER 2 immunohistochemistry for breast cancer cell blocks can be used in the same way as that used for histological specimens
- PMID: 26800514
- PMCID: PMC4819718
- DOI: 10.1002/dc.23433
HER 2 immunohistochemistry for breast cancer cell blocks can be used in the same way as that used for histological specimens
Abstract
Background: Human epidermal growth factor receptor 2 (HER2) testing of samples from recurrent or metastatic breast cancer is recommended by the 2013 update of the American Society of Clinical Oncology/College of American Pathologists guidelines. Although cytological analysis can be applied to several types of metastatic lesions, the practical method for HER2 testing of cytological specimens is yet to be resolved. We conducted immunohistochemical (IHC) staining for HER2 in breast cancer cell blocks (CBs) and compared the results with those from the corresponding histological specimens. In cases of discrepancy between the two types of specimen, the bright-field HER2 dual in situ hybridization (DISH) assay was performed.
Methods: CBs were prepared from 54 surgically excised breast cancers. The cells were fixed in 10% buffered formalin and embedded in paraffin. A Ventana BenchMark ULTRA (Roche Diagnostics) with anti-HER-2/neu (4B5) rabbit monoclonal primary antibody and INFORM HER2/neu Dual ISH DNA Probe Cocktail was used for the assays.
Results: Successful results were obtained in 52 of 54 CBs. Forty cases showed agreement between CBs and the histological specimens. No discrepancy was observed between the two types of specimens in cases where HER2 expression was positive. IHC results of CB in 12 discrepant cases were HER2 intermediate or negative. The DISH results of 11 of these cases were negative.
Conclusion: IHC staining of HER2 for breast cancer CBs can be used in the same way as that used for histological specimens, although the number of equivocal cases in CBs is greater than that in histological specimens. Diagn. Cytopathol. 2016;44:274-279. © 2016 The Authors Diagnostic Cytopathology Published by Wiley Periodicals, Inc.
Keywords: DISH; HER2; breast cancer; cell block; immunohistochemistry.
© 2016 The Authors Diagnostic Cytopathology Published by Wiley Periodicals, Inc.
Figures



Similar articles
-
HER2 assessment by bright-field dual in situ hybridization in cell blocks of recurrent and metastatic breast carcinoma.Cancer Cytopathol. 2019 Nov;127(11):684-690. doi: 10.1002/cncy.22184. Epub 2019 Sep 22. Cancer Cytopathol. 2019. PMID: 31544361 Free PMC article.
-
Bright-field HER2 dual in situ hybridization (DISH) assay on breast cancer cell blocks: a comparative study with histological sections.Breast Cancer. 2016 Nov;23(6):917-921. doi: 10.1007/s12282-015-0664-1. Epub 2016 Jan 8. Breast Cancer. 2016. PMID: 26746842 Free PMC article.
-
Determination of HER2/neu status: a pilot study comparing HER2/neu dual in situ hybridization DNA probe cocktail assay performed on cell blocks to immunohistochemisty and fluorescence in situ hybridization performed on histologic specimens.Arch Pathol Lab Med. 2014 Apr;138(4):553-8. doi: 10.5858/arpa.2013-0314-SA. Arch Pathol Lab Med. 2014. PMID: 24678687
-
The assessment of HER2 status in breast cancer: the past, the present, and the future.Pathol Int. 2016 Jun;66(6):313-24. doi: 10.1111/pin.12407. Epub 2016 Apr 7. Pathol Int. 2016. PMID: 27061008 Review.
-
Predictive markers in breast cancer: An update on ER and HER2 testing and reporting.Semin Diagn Pathol. 2015 Sep;32(5):362-9. doi: 10.1053/j.semdp.2015.02.011. Epub 2015 Feb 7. Semin Diagn Pathol. 2015. PMID: 25770732 Review.
Cited by
-
HER2 assessment by bright-field dual in situ hybridization in cell blocks of recurrent and metastatic breast carcinoma.Cancer Cytopathol. 2019 Nov;127(11):684-690. doi: 10.1002/cncy.22184. Epub 2019 Sep 22. Cancer Cytopathol. 2019. PMID: 31544361 Free PMC article.
-
Validation and Implementation of OptiView and EnVision FLEX Detection Systems for Immunocytochemical Staining Protocols of the Ten Most Commonly Used Diagnostic Markers in Routine Cytopathological Practice.Diagnostics (Basel). 2024 Mar 21;14(6):657. doi: 10.3390/diagnostics14060657. Diagnostics (Basel). 2024. PMID: 38535077 Free PMC article.
-
Clinical significance of evaluating hormone receptor and HER2 protein using cell block against metastatic breast cancer: a multi-institutional study.Oncotarget. 2019 Oct 1;10(55):5680-5689. doi: 10.18632/oncotarget.27163. eCollection 2019 Oct 1. Oncotarget. 2019. PMID: 31620243 Free PMC article.
-
Expression of tetraspanins NET-6 and CD151 in breast cancer as a potential tumor biomarker.Clin Exp Med. 2019 Aug;19(3):377-384. doi: 10.1007/s10238-019-00554-x. Epub 2019 Apr 20. Clin Exp Med. 2019. PMID: 31004251
-
Evaluation of the HER2 and Hormone Receptor Status in Metastatic Breast Cancer Using Cell Blocks: A Multi-Institutional Study.Acta Cytol. 2018;62(4):288-294. doi: 10.1159/000488382. Epub 2018 May 15. Acta Cytol. 2018. PMID: 29763896 Free PMC article.
References
-
- Wolff AC, Hammond MEH, Hicks DG, et al. Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. J Clin Oncol 2013;31:3997–4013. - PubMed
-
- Monaco SE, Wu Y, Teot LA Cai G. Assessment of estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2) status in the fine needle aspirates of metastatic breast carcinomas. Diagn Cytopathol 2013;41:308–315. - PubMed
-
- Shabaik A, Lin G, Peterson M, et al. Reliability of Her2/neu, estrogen receptor, and progestrone receptor testing by immunohistochemistry on cell block of FNA and serous effusions from patients with primary and metastatic breast carcinoma. Diagn Cytopathol 2011;39:328–332. - PubMed
-
- Bofin AM, Ytterhus B, Martin C, O'Leary JJ Hagmar BM. Detection and quantitation of HER‐2 gene amplification and protein expression in breast carcinoma. Am J Clin Pathol 2004;122:110–119. - PubMed
-
- Beatty BG, Bryant R, Wang W, et al. HER‐2/neu detection in fine‐needle aspirates of breast cancer: fluorescence in situ hybridization and immunocytochemical analysis. Am J Clin Pathol 2004;122:246–255. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous